Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma
| Autor: | Andrzej Mackiewicz, Sergiusz Nawrocki, V Filas, D. Bręborowicz, Aldona Karczewska |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Pathology Mammary gland Breast Neoplasms Disease-Free Survival Antigens CD Internal medicine Cytokine Receptor gp130 Tumor Cells Cultured medicine Carcinoma Humans RNA Messenger Interleukin 6 Survival rate Aged Neoplasm Staging Proportional Hazards Models Analysis of Variance Univariate analysis Membrane Glycoproteins biology Interleukin-6 business.industry Cancer Middle Aged Prognosis medicine.disease Receptors Interleukin-6 Gene Expression Regulation Neoplastic Survival Rate medicine.anatomical_structure Multivariate Analysis Interleukin-6 receptor biology.protein Female Breast carcinoma business Follow-Up Studies Signal Transduction |
| Zdroj: | Cancer. 88:2061-2071 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/(sici)1097-0142(20000501)88:9<2061::aid-cncr12>3.0.co;2-o |
| Popis: | BACKGROUND Interleukin-6 (IL-6) is secreted by normal epithelial breast cells but not by oncogene-transformed cells. Interleukin-6 is able to inhibit growth of breast carcinoma cells in culture. Interleukin-6 exerts its activity via two receptor subunits, IL-6R and glycoprotein 130 (gp130). The expression of these receptor subunits in breast tumors has been studied, but there are no previous reports of their prognostic significance, to the authors' knowledge. METHODS mRNA of IL-6, IL-6R, and gp130 was studied in 75 tumor samples obtained from breast carcinoma patients. Patients were followed for a maximum of 71 months (median follow-up, 61 months; 60 patients were followed for a minimum of 5 years or died during the observation period). Prognostic factors were analyzed in univariate and multivariate analysis. RESULTS mRNA specific to IL-6, IL-6R, and gp130 was detected in 57%, 53%, and 71% of breast carcinoma tissues, respectively. Expression was strongly correlated with earlier stages of the disease. In univariate analysis, expression of IL-6 and its receptor subunits proved to be a positive prognostic factor for overall survival (OS) and disease free survival (DFS). IL-6R and gp130 expression were good independent prognostic factors for OS. The 5-year OS of all patients was 66%. The 5-year OS in IL-6, IL-6R, and gp130 positive groups was 95%, 94%, and 90%, respectively, whereas in negative groups it was 26%, 31%, and 9%, respectively. CONCLUSIONS Expression of IL-6, IL-6R, and gp130 in breast carcinoma tissue is associated with earlier stages of the disease. In advanced stages, expression of IL-6 and its receptor subunits predicts better prognosis. Cancer 2000;88:2061–71. © 2000 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text